{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:31:05Z","timestamp":1786487465973,"version":"build-2736575974"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prostate cancer (PCa) is the second most prevalent malignancy in men worldwide, and accurate stratification of biochemical recurrence (BCR) risk remains challenging using conventional clinicopathological parameters alone. Identification of robust molecular biomarkers and integrated prognostic models is therefore of high clinical priority.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>RNA-seq count data and clinical annotations for 554 TCGA-PRAD samples were obtained and normalized to log2(CPM+1). Weighted gene co-expression network analysis (WGCNA) identified co-expression modules correlated with Gleason score, PSA, and pathologic T stage. Protein-protein interaction (PPI) network analysis with CytoHubba topological scoring defined consensus hub genes. Four machine learning algorithms - LASSO Cox regression, random forest, SVM, and XGBoost - were applied to construct and validate a prognostic risk model. Immune cell infiltration was quantified and a prognostic nomogram was constructed and evaluated by decision curve analysis. Hub gene expression was experimentally validated by qRT-PCR and ELISA in prostate cancer and normal prostatic epithelial cell lines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Five hub genes - EZH2, CDK1, AURKA, TOP2A, and CCNB1 - were identified within the turquoise WGCNA module, which showed the strongest correlations with Gleason score (r = 0.78), PSA (r = 0.68), and pathologic T stage (r = 0.62). LASSO Cox regression and random forest consensus selected EZH2, CDK1, and AURKA for a three-gene risk score (Risk Score = 0.312xEZH2 + 0.285xCDK1 + 0.241xAURKA). High-risk patients demonstrated markedly inferior BCR-free survival (HR = 3.21, 95% CI: 2.05\u20135.03; log-rank P &amp;lt; 0.0001), with time-dependent AUCs of 0.821, 0.842, and 0.836\u00a0at 1, 3, and 5\u00a0years, respectively. Multivariate Cox regression confirmed the risk score as an independent prognostic factor (HR = 2.87; P &amp;lt; 0.001). A nomogram integrating the risk score with clinical parameters showed superior net benefit by decision curve analysis. Hub-high tumors exhibited reduced CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell infiltration, elevated M2 macrophage abundance, and upregulated immune checkpoints (PD-L1, CTLA4, TIM-3, LAG3). All hub genes were confirmed overexpressed at both mRNA and protein levels in PCa cell lines by qRT-PCR and ELISA.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>EZH2, CDK1, and AURKA constitute an internally validated prognostic risk signature in PCa that links cell cycle dysregulation to an immunosuppressive tumor microenvironment. This signature provides clinically actionable risk stratification and highlights candidate therapeutic targets in prostate cancer.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgene.2026.1877595","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:10:19Z","timestamp":1786486219000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Machine learning-based identification of hub genes and prognostic biomarkers in prostate cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Guquan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Urology, The Second People\u2019s Hospital of Yueqing","place":["Yueqing City, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiefeng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second People\u2019s Hospital of Yueqing","place":["Yueqing City, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linfu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second People\u2019s Hospital of Yueqing","place":["Yueqing City, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyou","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Urology, The Second People\u2019s Hospital of Yueqing","place":["Yueqing City, Zhejiang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"5459","DOI":"10.1016\/j.csbj.2025.11.061","article-title":"A systems biology approach to unveil shared therapeutic targets and pathological pathways across major human cancers","volume":"27","author":"Alam","year":"2025","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"B2","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s12894-023-01350-2","article-title":"Prediction of biochemical recurrence after laparoscopic radical prostatectomy","volume":"23","author":"Bejrananda","year":"2023","journal-title":"BMC Urol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12894-025-01690-1","article-title":"Prognostic value of intraductal carcinoma subtypes and postoperative radiotherapy for localized prostate cancer","volume":"25","author":"Cao","year":"2025","journal-title":"BMC Urol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1009634","DOI":"10.3389\/fimmu.2022.1009634","article-title":"The established chemokine-related prognostic gene signature in prostate cancer: implications for anti-androgen and immunotherapies","volume":"13","author":"Chen","year":"2022","journal-title":"Front. Immunol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1608711","DOI":"10.3389\/fcell.2025.1608711","article-title":"Aurora kinase-A expression heterogeneity and potential benefit of combination therapy in prostate adenocarcinoma","volume":"13","author":"Chen","year":"2025","journal-title":"Front. Cell Dev. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1186\/s12951-024-03070-7","article-title":"Targeting AURKA with multifunctional nanoparticles in CRPC therapy","volume":"22","author":"Deng","year":"2024","journal-title":"J. Nanobiotechnology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.3390\/biom12111617","article-title":"EZH2 as a prognostic factor and its immune implication with molecular characterization in prostate cancer: an integrated multi-omics in silico analysis","volume":"12","author":"Du","year":"2022","journal-title":"Biomolecules"},{"key":"B8","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.euo.2025.03.016","article-title":"Prediction of prostate cancer biochemical recurrence after radical prostatectomy by collagen models using multiomic profiles","volume":"9","author":"Frantzi","year":"2025","journal-title":"Eur. Urol. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/S0140-6736(24)00367-2","article-title":"Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories, 1990-2021: a systematic analysis for the global burden of disease study 2021","volume":"403","year":"2024","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13046-023-02781-3","article-title":"Deubiquitylase YOD1 regulates CDK1 stability and drives triple-negative breast cancer tumorigenesis","volume":"42","author":"Han","year":"2023","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"e2308045","DOI":"10.1002\/advs.202308045","article-title":"EZH2 inhibition enhances PD-L1 protein stability through USP22-mediated deubiquitination in colorectal cancer","volume":"11","author":"Huang","year":"2024","journal-title":"Adv. Sci. (Weinh)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"611","DOI":"10.21873\/cgp.20525","article-title":"Prognostic significance of EZH2-related gene variants in patients with prostate cancer undergoing androgen deprivation therapy","volume":"22","author":"Huang","year":"2025","journal-title":"Cancer Genomics Proteomics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s13578-025-01485-9","article-title":"PA2G4 in CAFs promotes biochemical recurrence of prostate cancer via H3K18la","volume":"15","author":"Ji","year":"2025","journal-title":"Cell Biosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1160972","DOI":"10.3389\/fonc.2023.1160972","article-title":"Subtype and prognostic analysis of immunogenic cell death-related gene signature in prostate cancer","volume":"13","author":"Kang","year":"2023","journal-title":"Front. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e193162","DOI":"10.1172\/JCI193162","article-title":"USP22 drives tumor immune evasion and checkpoint blockade resistance through EZH2-mediated epigenetic silencing of MHC-I","volume":"136","author":"Liu","year":"2025","journal-title":"J. Clin. Invest"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2024","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3390\/cells13231999","article-title":"Therapeutic exploitation of neuroendocrine transdifferentiation drivers in prostate cancer","volume":"13","author":"Maylin","year":"2024","journal-title":"Cells"},{"key":"B18","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1158\/1541-7786.MCR-24-0791","article-title":"Single-cell and spatial transcriptomics reveal a tumor-associated macrophage subpopulation that mediates prostate cancer progression and metastasis","volume":"23","author":"Mei","year":"2025","journal-title":"Mol. Cancer Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"eado8231","DOI":"10.1126\/sciadv.ado8231","article-title":"SRSF6 modulates histone-chaperone HIRA splicing to orchestrate AR and E2F activity in prostate cancer","volume":"10","author":"Montero-Hidalgo","year":"2024","journal-title":"Sci. Adv."},{"key":"B20","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1159\/000541881","article-title":"The immune microenvironment in prostate cancer: a comprehensive review","volume":"103","author":"Novysedlak","year":"2024","journal-title":"Oncology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"e40134","DOI":"10.1097\/MD.0000000000040134","article-title":"Unveiling novel prognostic biomarkers and therapeutic targets for HBV-Associated hepatocellular carcinoma through integrated bioinformatic analysis","volume":"103","author":"Ren","year":"2024","journal-title":"Med. Baltim."},{"key":"B22","doi-asserted-by":"publisher","first-page":"43908","DOI":"10.1038\/s41598-025-27704-4","article-title":"Unravelling TPX2-centered co-expression networks as key drivers of aggressive prostate cancer","volume":"15","author":"Sheibani-Tezerji","year":"2025","journal-title":"Sci. Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"eadf6724","DOI":"10.1126\/scitranslmed.adf6724","article-title":"Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies","volume":"15","author":"Shi","year":"2023","journal-title":"Sci. Transl. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12967-023-04807-y","article-title":"Integrating single-cell and bulk RNA sequencing data unveils antigen presentation and process-related CAFs and establishes a predictive signature in prostate cancer","volume":"22","author":"Wang","year":"2024","journal-title":"J. Transl. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"10906","DOI":"10.1038\/s41598-023-38117-6","article-title":"The role of TOP2A in immunotherapy and vasculogenic mimicry in non-small cell lung cancer and its potential mechanism","volume":"13","author":"Wu","year":"2023","journal-title":"Sci. Rep."},{"key":"B26","doi-asserted-by":"publisher","first-page":"e006581","DOI":"10.1136\/jitc-2022-006581","article-title":"Androgen receptor blockade resistance with enzalutamide in prostate cancer results in immunosuppressive alterations in the tumor immune microenvironment","volume":"11","author":"Xu","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1250033","DOI":"10.3389\/fendo.2023.1250033","article-title":"Identification of key genes and pathways in adrenocortical carcinoma: evidence from bioinformatic analysis","volume":"14","author":"Yin","year":"2023","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1570378","DOI":"10.3389\/fimmu.2025.1570378","article-title":"Multi-omics identification of a polyamine metabolism related signature for hepatocellular carcinoma and revealing tumor microenvironment characteristics","volume":"16","author":"Yu","year":"2025","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cancergen.2023.07.005","article-title":"Identification of a novel stemness-related signature with appealing implications in discriminating the prognosis and therapy responses for prostate cancer","author":"Zhang","year":"2023","journal-title":"Cancer Genet."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1468875","DOI":"10.3389\/fimmu.2024.1468875","article-title":"Machine learning-based selection of immune cell markers in osteosarcoma: prognostic determination and validation of CLK1 in disease progression","volume":"15","author":"Zhang","year":"2024","journal-title":"Front. Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1661679","DOI":"10.3389\/fimmu.2025.1661679","article-title":"Integrative modeling of malignant epithelial programs in EGFR-Mutant LUAD via single-cell transcriptomics and multi-algorithm machine learning","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/0008-5472.CAN-23-1176","article-title":"Genomic and evolutionary characterization of concurrent intraductal carcinoma and adenocarcinoma of the prostate","volume":"84","author":"Zhao","year":"2024","journal-title":"Cancer Res."},{"key":"B33","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41586-024-07888-x","article-title":"CDK5-cyclin B1 regulates mitotic fidelity","volume":"633","author":"Zheng","year":"2024","journal-title":"Nature"},{"key":"B34","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1186\/s12967-025-06457-8","article-title":"An anti-androgen resistance-related gene signature acts as a prognostic marker and increases enzalutamide efficacy via PLK1 inhibition in prostate cancer","volume":"23","author":"Zhuang","year":"2025","journal-title":"J. Transl. Med."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1877595\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T22:10:20Z","timestamp":1786486220000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1877595\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":34,"alternative-id":["10.3389\/fgene.2026.1877595"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1877595","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"1877595"}}